Recursion Pharmaceuticals (RXRX) Free Cash Flow (2020 - 2026)

Recursion Pharmaceuticals has reported Free Cash Flow for 7 years, with the latest figure at -$81.1 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 39.07% year-over-year to -$81.1 million; the trailing twelve-month figure through Mar 2026 stood at -$326.3 million (up 17.82% YoY), and the FY2025 full-year result was -$378.3 million, down 1.45% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$81.1 million, down from -$52.5 million in the prior quarter.
• The five-year high for Free Cash Flow was $73.0 million in Q1 2022, with the low at -$133.1 million in Q1 2025.
• Historically, Free Cash Flow has averaged -$73.1 million across 5 years, with a median of -$78.1 million in 2022.
• The largest YoY upside for Free Cash Flow was 245.59% in 2022 against a maximum downside of 420.65% in 2022.
• Recursion Pharmaceuticals' Free Cash Flow stood at -$78.7 million in 2022, then climbed by 15.35% to -$66.6 million in 2023, then plunged by 75.19% to -$116.7 million in 2024, then surged by 55.01% to -$52.5 million in 2025, then tumbled by 54.44% to -$81.1 million in 2026.
• The last three Free Cash Flow figures came in at -$81.1 million (Q1 2026), -$52.5 million (Q4 2025), and -$117.1 million (Q3 2025), per Business Quant data.